Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)
Close on Nov 17, 2026Market cap $82.56BP/E –Yield –
Moderna total assets
Total assets on the balance sheet at the end of each period.
Moderna's total assets was $10.96B at Jun 30, 2026. For fiscal 2025 it was $12.34B, down 12.8% from the year before. The highest annual figure on record is $25.86B in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.34B | -12.8% |
| FY2024 | Dec 31, 2024 | $14.14B | -23.2% |
| FY2023 | Dec 31, 2023 | $18.43B | -28.7% |
| FY2022 | Dec 31, 2022 | $25.86B | +4.8% |
| FY2021 | Dec 31, 2021 | $24.67B | +236.2% |
| FY2020 | Dec 31, 2020 | $7.34B | +361.6% |
| FY2019 | Dec 31, 2019 | $1.59B | -19.0% |
| FY2018 | Dec 31, 2018 | $1.96B | +80.9% |
| FY2017 | Dec 31, 2017 | $1.08B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $10.96B | -8.7% |
| Q1 FY2026 | Mar 31, 2026 | $11.49B | -9.6% |
| Q4 FY2025 | Dec 31, 2025 | $12.34B | -12.8% |
| Q3 FY2025 | Sep 30, 2025 | $12.14B | -23.2% |
| Q2 FY2025 | Jun 30, 2025 | $12.01B | -23.4% |
| Q1 FY2025 | Mar 31, 2025 | $12.70B | -24.1% |
| Q4 FY2024 | Dec 31, 2024 | $14.14B | -23.2% |
| Q3 FY2024 | Sep 30, 2024 | $15.80B | -18.8% |
| Q2 FY2024 | Jun 30, 2024 | $15.68B | -28.3% |
| Q1 FY2024 | Mar 31, 2024 | $16.73B | -30.7% |
| Q4 FY2023 | Dec 31, 2023 | $18.43B | -28.7% |
| Q3 FY2023 | Sep 30, 2023 | $19.45B | -25.4% |
| Q2 FY2023 | Jun 30, 2023 | $21.88B | -16.0% |
| Q1 FY2023 | Mar 31, 2023 | $24.13B | -12.6% |
| Q4 FY2022 | Dec 31, 2022 | $25.86B | +4.8% |
| Q3 FY2022 | Sep 30, 2022 | $26.06B | +24.5% |
| Q2 FY2022 | Jun 30, 2022 | $26.04B | +61.2% |
| Q1 FY2022 | Mar 31, 2022 | $27.61B | +117.5% |
| Q4 FY2021 | Dec 31, 2021 | $24.67B | +236.2% |
| Q3 FY2021 | Sep 30, 2021 | $20.92B | +349.9% |
| Q2 FY2021 | Jun 30, 2021 | $16.15B | +363.4% |
| Q1 FY2021 | Mar 31, 2021 | $12.69B | +514.0% |
| Q4 FY2020 | Dec 31, 2020 | $7.34B | +361.6% |
| Q3 FY2020 | Sep 30, 2020 | $4.65B | +192.3% |
| Q2 FY2020 | Jun 30, 2020 | $3.49B | +106.9% |
| Q1 FY2020 | Mar 31, 2020 | $2.07B | +14.5% |
| Q4 FY2019 | Dec 31, 2019 | $1.59B | -19.0% |
| Q3 FY2019 | Sep 30, 2019 | $1.59B | +46.7% |
| Q2 FY2019 | Jun 30, 2019 | $1.69B | – |
| Q1 FY2019 | Mar 31, 2019 | $1.81B | – |
| Q4 FY2018 | Dec 31, 2018 | $1.96B | – |
| Q4 FY2017 | Dec 31, 2017 | $1.08B | – |
See a number that looks wrong?